Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Associations between androgen exposure, PCOS, and transmasculine individuals with central serous chorioretinopathy
Danny A. Mammo, MD, a vitreoretinal surgeon and uveitis specialist at the Cole Eye Institute at Cleveland Clinic, presented research on the association between androgen exposure and central serous chorioretinopathy (CSCR) at the 2025 scientific meeting of the American Society…
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients – GlobeNewswire
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients GlobeNewswire Source: Author: | Date: 2025-08-21 05:32:00 Source: Author: | Date: 2025-08-21 05:32:00
Natural molecule discovery could help glaucoma patients – Medical Xpress
Natural molecule discovery could help glaucoma patients Medical Xpress Source: Author: | Date: 2025-08-20 18:00:00 Source: Author: | Date: 2025-08-20 18:00:00
VivaVision Biotech appoints Quan Dong Nguyen to its scientific advisory board
(Image credit: AdobeStock) VivaVision Biotech Co., Ltd., appointed Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, to its scientific advisory board. Nguyen is a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine. He is also…
The emerging era of presbyopia-correcting eye drops: What’s next?
(Image Credit: AdobeStock/taffpixture) Since 2021, only 1 prescription eye drop for the correction of presbyopia, pilocarpine HCI ophthalmic solution 1.25% (Vuity; AbbVie), has been available, with additional options expected soon. In early 2025, a second eye drop, pilocarpine HCI ophthalmic…
Iantrek sees $42M fundraising for alternative glaucoma surgery launch – fiercebiotech.com
Iantrek sees $42M fundraising for alternative glaucoma surgery launch fiercebiotech.com Source: Author: | Date: 2025-08-20 07:00:00 Source: Author: | Date: 2025-08-20 07:00:00
AEVR’s executive director on #SeeWhatMatters and safeguarding the National Eye Institute
#SeeWhatMatters is a national advocacy campaign to raise awareness about the importance of federally funded vision research and to protect the independence of the National Eye Institute amid proposed structural changes to the NIH. (Image courtesy of #SeeWhatMatters) The Alliance…
UK MHRA approves phase 2a study for ANXV for diabetic retinopathy
(Image credit: AdobeStock/Janis Smits) UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the start of a clinical Proof of Concept phase 2a study with the drug candidate ANXV in the eye disease diabetic retinopathy (DR). Patients with newly…
Opthea parts with CEO, lays off over 80% of company
(Image Credit: AdobeStock/Andrii Yalanskyi) Opthea has released a corporate update following its settlement of the Development Funding Agreement (“DFA”) with the 2 investors under the DFA.1 The company previously provided an update in April 20252 stating its intention to lay…
FDA clears IND for Opus Genetics’ OPGx-BEST1 gene therapy for inherited retinal disease
(Image Credit: AdobeStock/Corona Borealis) The US Food and Drug Administration (FDA) has accepted Opus Genetics’ Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal disease (IRD). Best disease, or vitelliform macular…